CPG 7909 : Coley Pharmaceutical Group : TLR9 agonist

CPG 7909 Added to First Line Taxane/Platinum for Advanced NSCLC: a Randomized, Controlled Phase II Study (ASCO)
Abstract of a phase II study presented at the ASCO 2005 annual meeting that found CPG 7909 added to a taxane/platinum regimen for first-line NSCLC is well-tolerated and appears to improve objective response. Additional studies are warranted to document clinical benefit. [5/05]

CPG 7909 - Clinical Trials (ClinicalTrials.gov)